Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma

Official record

Identifier

NCT07845617

Recruiting locations

country

United States

Interventions studied

Hepatic Artery Infusion Pump (HAIP)Floxuridine (FUDR)

Lead sponsor

AdventHealth

Target enrolment

10 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Sep 29, 2026

Last updated on the registry

Sep 29, 2026

Age

18 Years – 80 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age 18-80 years
* Histologically confirmed pancreatic or duodenal adenocarcinoma
* Completed or currently receiving curative-intent treatment
* Evidence of isolated or liver-dominant metastases (radiographic or clinical)
* Deemed clinically eligible for hepatic artery infusion pump (HAIP) placement and floxuridine (FUDR)-based chemotherapy by a multidisciplinary oncology team
* Scheduled for HAIP placement at AdventHealth Orlando

Exclusion Criteria:

\- Patients who are clinically ineligible for HAIP placement or FUDR therapy are excluded

Indexed under

Liver Cancer